Emiliem, Inc. - Molecularly Targeted Oncology Therapeutics, Multi-Kinase Inhibitor

About

Emiliem starts by selecting targets and biological pathways it considers to be highly relevant in a number of diseases, examines the possibility of novel chemical space related to inhibiting combinations of these targets, then designs and/or acquires compounds that it expects to be efficacious in the desired multi-functional way.

When acquiring candidate programs, the proposed assets must have reached the proof-of-concept stage of efficacy in relevant animal models. Each program must have a sound scientific basis, a lead compound with additional back-up compounds, and the opportunity to create additional novel chemistry within the project. The Company’s initial focus is on cancer therapeutics, but its intellectual property addresses other indications as well, including inflammatory and metabolic diseases.

The Company has entered into an exclusive licensing agreement with the National Institutes of Health (NIH) for the world-wide rights to develop and commercialize a series of compounds that modulate key biological pathways known to be important in the progression of cancer and other proliferative and inflammatory diseases. The lead compound (EM101) is positioned for clinical trials within a year and targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate. Current data indicate that EM101 is an mTOR inhibitor, active through rapamycin sensitive and insensitive mechanisms. In addition to the lead compound, Emiliem has identified four additional compound templates that will be used to generate back-up compounds to EM101 and novel analogs that can lead to new composition of matter patents.

We are applying unique knowledge of biomarkers at the design stage of drug discovery. This will facilitate the identification of patients likely to respond to treatment as well as those at risk for adverse drug reactions. It will further allow us to monitor the desired outcomes in the first human clinical trials.Our ability to couple drug discovery with biomarker identification and implementation will increase the likelihood of achieving clinical trial endpoints and receiving approval to market our drug candidates



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	About Emiliem starts by selecting targets and biological pathways it considers to be highly relevant in a number of diseases, examines the possibility of novel chemical space related to inhibiting combinations of these targets, then designs and/or acquires compounds that it expects to be efficacious in the desired multi-functional way. When acquiring candidate programs, the proposed assets must have reached the proof-of-concept stage of efficacy in relevant animal models. Each program must have a sound scientific basis, a lead compound with additional back-up compounds, and the opportunity to create additional novel chemistry within the project. The Company’s initial focus is on cancer therapeutics, but its intellectual property addresses other indications as well, including inflammatory and metabolic diseases. The Company has entered into an exclusive licensing agreement with the National Institutes of Health (NIH) for the world-wide rights to develop and commercialize a series of compounds that modulate key biological pathways known to be important in the progression of cancer and other proliferative and inflammatory diseases. The lead compound (EM101) is positioned for clinical trials within a year and targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate. Current data indicate that EM101 is an mTOR inhibitor, active through rapamycin sensitive and insensitive mechanisms. In addition to the lead compound, Emiliem has identified four additional compound templates that will be used to generate back-up compounds to EM101 and novel analogs that can lead to new composition of matter patents. We are applying unique knowledge of biomarkers at the design stage of drug discovery. This will facilitate the identification of patients likely to respond to treatment as well as those at risk for adverse drug reactions. It will further allow us to monitor the desired outcomes in the first human clinical trials.Our ability to couple drug discovery with biomarker identification and implementation will increase the likelihood of achieving clinical trial endpoints and receiving approval to market our drug candidates